Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy
Status:
Completed
Trial end date:
2019-12-30
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, parallel study to evaluate effect of exenatide on
24h-UAER in patients with diabetic nephropathy.
Screening will be made to select eligible participants before intervention. The trial will
include 2-week run-in period of stable doses of glargine plus lispro insulin and 24-week
treatment period. After the run-in period, patients were randomly assigned to one of two
groups for antihyperglycaemic therapies for a total of 24-weeks: glargine plus exenatide and
continued glargine plus lispro insulin. The treatment of exenatide will be initiated by 5ug
bid, and uptitrated to 10 ug bid after 4 weeks and then maintained at 10ug bid until the
completion of the study. Lispro insulin will be initially treated according to the insulin
dosage of previous antihyperglycaemic therapies, and further titrated up at 4-week intervals
until to reach the target fasting blood glucose (FPG).